{
  "emaEpar": [],
  "fdaDrugLabel": [
    {
      "brand": "Idamycin PFS",
      "indication": "INDICATIONS AND USAGE IDAMYCIN PFS Injection in combination with other approved antileukemic drugs is indicated for the treatment of acute myeloid leukemia (AML) in adults. This includes French-American-British (FAB) classifications M1 through M7.",
      "manufacturer": "Pharmacia & Upjohn Company LLC",
      "splSetId": "0a5a6d93-cc1e-4d7f-8da1-446c134503b3"
    },
    {
      "brand": "Idarubicin Hydrochloride",
      "indication": "INDICATIONS AND USAGE Idarubicin Hydrochloride injection, USP in combination with other approved antileukemic drugs is indicated for the treatment of acute myeloid leukemia (AML) in adults. This includes French-American-British (FAB) classifications M1 through M7.",
      "manufacturer": "Hikma Pharmaceuticals USA Inc.",
      "splSetId": "7c20b574-285b-49eb-a98e-6752e4bb481d"
    },
    {
      "brand": "Idarubicin Hydrochloride",
      "indication": "INDICATIONS AND USAGE Idarubicin Hydrochloride injection, USP in combination with other approved antileukemic drugs is indicated for the treatment of acute myeloid leukemia (AML) in adults. This includes French-American-British (FAB) classifications M1 through M7.",
      "manufacturer": "Hikma Pharmaceuticals USA Inc.",
      "splSetId": "b9b337d5-50f7-4ea9-9df4-72c86e4c0b91"
    },
    {
      "brand": "Idarubicin Hydrochloride",
      "indication": "INDICATIONS AND USAGE Idarubicin hydrochloride injection in combination with other approved antileukemic drugs is indicated for the treatment of acute myeloid leukemia (AML) in adults. This includes French-American-British (FAB) classifications M1 through M7.",
      "manufacturer": "Teva Parenteral Medicines, Inc.",
      "splSetId": "d521b65f-3fd2-4efe-8cab-b444921dd223"
    }
  ],
  "id": "Idarubicin_Hydrochloride",
  "nciThesaurus": {
    "casRegistry": "57852-57-0",
    "chebiId": "",
    "chemicalFormula": "C26H27NO9.HCl",
    "definition": "The hydrochloride salt of the anthracycline antineoplastic antibiotic idarubicin.  Idarubicin intercalates into DNA and inhibits topoisomerase II, thereby inhibiting DNA replication and ultimately, interfering with RNA and protein synthesis.  Due to its high lipophilicity, idarubicin penetrates cell membranes more efficiently than other anthracycline antibiotic compounds",
    "fdaUniiCode": "5VV3MDU5IE",
    "identifier": "C1587",
    "preferredName": "Idarubicin Hydrochloride",
    "semanticType": "Organic Chemical",
    "subclassOf": [
      "C1594"
    ],
    "synonyms": [
      "IDARUBICIN HYDROCHLORIDE",
      "IMI-30",
      "Idamycin",
      "Idamycin PFS",
      "Idarubicin HCl",
      "Idarubicin Hydrochloride",
      "Idarubicin hydrochloride",
      "SC-33428",
      "Zavedos"
    ]
  }
}